Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

AstraZeneca

1,583.50 SEK+1.51 %6/10 17:29
Less than 1K followers

AZN

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor views
Compare
+1.51 %
+1.80 %
-15.00 %
-15.79 %
-7.04 %
-0.28 %
+7.87 %
+50.41 %
+8,564.61 %

AstraZeneca is a global pharmaceutical company focused on the research, development and marketing of prescription medicines, primarily for the treatment of diseases in the therapeutic areas of respiratory, cardiovascular/metabolic and cancer. In addition to its core business, the company also has a focus on the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in all global regions and is headquartered in Cambridge, UK.

Read more
Market cap
2.46T SEK
Turnover
764.65M SEK
Revenue
540.24B
EBIT %
23.4 %
P/E
26.09
Dividend yield-%
1.86 %
Revenue and EBIT-%
EPS and dividend
Financial calendar
30/10
2026

Interim report Q3'26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Press release2026-10-06 08:06

AstraZeneca: Alexion to showcase Phase III data in hypophosphatasia and hypoparathyroidism at ASBMR 2026 Annual Meeting

AstraZeneca
Press release2026-10-05 18:11

AstraZeneca opens new global strategic R&D centre in Kendall Square, Cambridge, Massachusetts

AstraZeneca
Press release2026-10-05 13:11

AstraZeneca completes equity investment in Summit Therapeutics

AstraZeneca

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release2026-10-02 08:31

AstraZeneca and Daiichi Sankyo announce clinical collaboration with Summit Therapeutics to evaluate Datroway in combination with ivonescimab across multiple tumour types

AstraZeneca
Press release2026-09-29 08:04

AstraZeneca announces strategic equity investment and clinical collaboration with Summit Therapeutics to advance leading ADC combination strategy in cancer

AstraZeneca
Press release2026-09-25 08:01

AstraZeneca: Perioperative Imfinzi plus neoadjuvant enfortumab vedotin granted Priority Review in the US for patients with muscle-invasive bladder cancer

AstraZeneca
Press release2026-09-24 08:04

AstraZeneca: Alexion advances pioneering leadership in gMG care with data at 2026 AANEM Annual Meeting and MGFA Scientific Session

AstraZeneca
Press release2026-09-23 08:01

AstraZeneca: Trixeo approved in the EU for the maintenance treatment of asthma

AstraZeneca
Press release2026-09-18 15:08

AstraZeneca: Klygefa (gefurulimab) recommended for approval in the EU by CHMP for the treatment of adults with generalised myasthenia gravis (gMG)

AstraZeneca
Press release2026-09-18 14:05

AstraZeneca: Enhertu recommended for approval in the EU by CHMP as adjuvant treatment for patients with residual disease after neoadjuvant treatment for HER2-positive early breast cancer

AstraZeneca
Press release2026-09-18 08:04

AstraZeneca: Efzimfotase alfa granted Priority Review in the US as treatment for patients with hypophosphatasia aged 2 years and older

AstraZeneca
Press release2026-09-14 08:06

AstraZeneca: Enhertu demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial

AstraZeneca
Press release2026-09-14 08:01

AstraZeneca: Update on SERENA-4 Phase III trial of Etcamah in combination with palbociclib in upfront 1st-line advanced ER-positive breast cancer

AstraZeneca
Press release2026-09-14 07:51

AstraZeneca: Tagrisso demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial

AstraZeneca
Press release2026-09-08 15:02

AstraZeneca: Imfinzi+Imdelltra improved OS in small cell lung

AstraZeneca
Press release2026-09-08 13:51

AstraZeneca: Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials

AstraZeneca
Press release2026-09-07 08:00

AstraZeneca: Etcamah in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer

AstraZeneca
Press release2026-09-01 08:31

AstraZeneca: Enhertu plus pertuzumab approved in the EU as first new regimen in more than a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer

AstraZeneca
Press release2026-09-01 08:05

AstraZeneca completes global license agreement for oral EGFR inhibitor Zegfrovy for lung cancer

AstraZeneca
Press release2026-09-01 08:02

AstraZeneca: Tagrisso plus Orpathys demonstrated statistically significant and highly clinically meaningful improvement in progression-free survival in 1st-line MET-overexpressing EGFR-mutated lung cancer

AstraZeneca